The Global Point-of-Care Molecular Diagnostics Market is projected to grow at a CAGR of 10.2% from 2026 to 2033, according to a new report published by Verified Market Reports®. The report reveals ...

Myriad Genetics and Lumea Inc. partner to integrate molecular diagnostics into Lumea's digital pathology platform, enhancing cancer care efficiency. Myriad Genetics and Lumea Inc. have announced a ...

SALT LAKE CITY and BOSTON, Sept. 23, 2025 /PRNewswire/ -- Myriad Genetics (MYGN) (Nasdaq: MYGN), a leader in molecular diagnostic testing and precision medicine, and SOPHiA GENETICS (SOPH) (Nasdaq: ...

"Driven by Advances in Genetic and Cancer Testing, Molecular Diagnostics Emerges as a Critical Tool for Early Disease Detection and Risk Prediction"Boston, Oct. 22, 2025 (GLOBE NEWSWIRE) -- According ...

This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer .

All authors are employees of the UnitedHealth Group. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial ...

Myriad Genetics ( ($MYGN) ) has released its Q3 earnings. Here is a breakdown of the information Myriad Genetics presented to its investors.

The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...

Labroots is excited to announce our 14th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2026 held on May 13th, 2026! The Precision Medicine: Genomics, ...

Labroots is excited to announce our 12th Annual Precision Medicine: Genomics, Genetics & Molecular Diagnostics Virtual Event Series 2024 held on May 15, 2024! The Precision Medicine: Genomics, ...